Skip to main content
SpringerLink
Log in

Gene Transfer for Generation of Tumor and Leukemia Vaccines

  • Protocol
Cytokines and Colony Stimulating Factors

Part of the book series: Methods in Molecular Biology ((MIMB,volume 215))

  • 522 Accesses

Abstract

Tumor vaccine strategies aim to compensate for the reduced immunogenicity of tumor cells (1-4). Neoplastic cells fail to induce an effective antineoplastic immune response for a number of reasons, such as defective antigen-processing mechanisms, decreased levels of MHC expression, or lack of costimulatory molecules. In tumor vaccine generation, these deficits may be overcome either by introducing genes encoding for immunomodulatory molecules into the tumor vaccine cells or by employing professional antigen-presenting cells such as dendritic cells (DCs) that have been primed with tumor antigens. For preparation of tumor vaccine cells, choices have to be made with regard to autologous versus allogeneic target cells, the immunomodulatory genes used for transduction, and the appropriate gene transfer system used for the introduction of immunomodulatory molecules.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pardoll, D. M. (1998) Cancer vaccines. Nat. Med. 4, 525–531.

    CAS  Google Scholar 

  2. Brenner, M. K. (2001) Gene transfer and the treatment of haematological malignancy. J. Intern. Med. 249, 345–358.

    CAS  Google Scholar 

  3. Wierda, W. G. and Kipps, T. J. (2000) Gene therapy of hematologic malignancies. Semin. Oncol. 27, 502–511.

    CAS  Google Scholar 

  4. Van Tendeloo, V. F., Van Broeckhoven, C., and Berneman, Z. N. (2001) Genebased cancer vaccines: an ex vivo approach. Leukemia 15, 545–558.

    Google Scholar 

  5. Stripecke, R., Skelton, D. C., Gruber, T., Afar, D., Pattengale, R K., Witte, O. N., et al. (1998) Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocytemacrophage colony-stimulating factor. Hum. Gene Ther. 9, 2049–2062.

    CAS  Google Scholar 

  6. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., et al. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713–716.

    CAS  Google Scholar 

  7. Schadendorf, D., Czarnetzki, B. M., and Wittig, B. (1995) Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma. J. Mol. Med. 73, 473–477.

    CAS  Google Scholar 

  8. Dilloo, D., Bacon, K., Holden, W., Zhong, W., Burdach, S., Zlotnik, A., et al. (1996) Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med. 2, 1090–1095.

    CAS  Google Scholar 

  9. Zhang, W., He, L., Yuan, Z., Xie, Z., Wang, J,. Hamada, H., et al. (1999) Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum. Gene Ther. 10, 1151–1161.

    CAS  Google Scholar 

  10. Heuer, J. G., Tucker-McClung, C., Gonin, R., and Hock, R. A. (1996) Retrovirusmediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one. Hum. Gene Ther. 7, 2059–2068.

    CAS  Google Scholar 

  11. Dunussi-Joannopoulos, K., Weinstein, H. J., Nickerson, P. W., Strom, T. B., Burakoff, S. J., Croop, J. M., et al. (1996) Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87, 2938–2946.

    CAS  Google Scholar 

  12. Dilloo, D., Brown, M., Roskrow, M., Zhong, W., Holladay, M., Holden, W., et al. (1997) CD40 ligand induces an antileukemia immune response in vivo. Blood 90, 1927–1933.

    CAS  Google Scholar 

  13. Bonnet, M. C., Tartaglia, J., Verdier, F., Kourilsky, P., Lindberg, A., Klein, M., et al. (2000) Recombinant viruses as a tool for therapeutic vaccination against human cancer. Immunol. Lett. 74, 11–25.

    CAS  Google Scholar 

  14. Todryk, S. M., Birchall, L. J., Erlich, R., Halanek, N., Orleans-Lindsay, J. K., and Dalgleish, A. G. (2001) Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology 102, 190–198.

    CAS  Google Scholar 

  15. Kohn, D. B. (2001) Gene therapy for genetic haematological disorders and immunodeficiencies. J. Intern. Med. 249, 379–390.

    CAS  Google Scholar 

  16. Stripecke, R., Cardoso, A. A., Pepper, K. A., Skelton, D. C., Yu, X. J., Mascar-enhas, L., et al. (2000) Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage-colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 96, 1317–1326.

    CAS  Google Scholar 

  17. Bubenik, J. (2001) Genetically engineered dendritic cell-based cancer vaccines, [review]. Int. J. Oncol. 18, 475–478.

    CAS  Google Scholar 

  18. Dietz, A. B., Bulur, P. A., Brown, C. A., Pankratz, V. S., and Vuk-Pavlovic, S. (2001) Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression. Gene Ther. 8, 419–423.

    CAS  Google Scholar 

  19. Regn, S., Raffegerst, S., Chen, X., Schendel, D., Kolb, H. J., and Roskrow, M. (2001) Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant. 27, 53–64.

    CAS  Google Scholar 

  20. Esche, C., Shurin, M. R., and Lotze, M. T. (1999) The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther. 1, 72–81.

    CAS  Google Scholar 

  21. Hanenberg, H., Xiao, X. L., Dilloo, D., Hashino, K., Kato, I., and Williams, D. A. (1996) Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2, 876–882.

    CAS  Google Scholar 

  22. Moritz, T., Patel, V. P., and Williams, D. A. (1994) Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J. Clin. Invest. 93, 1451–1457.

    CAS  Google Scholar 

  23. Zhang, W. W. (1999) Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6, 113–138.

    CAS  Google Scholar 

  24. Greenberg, D. S. (2000) Stricter regulation proposed for US gene-therapy trials. Lancet 355, 1977.

    CAS  Google Scholar 

  25. Kochanek, S., Clemens, P. R., Mitani, K., Chen, H. H., Chan, S., and Caskey, C. T. (1996) A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA 93, 5731–5736.

    CAS  Google Scholar 

  26. Wolfe, D., Goins, W. F., Yamada, M., Moriuchi, S., Krisky, D. M., Oligino, T. J., et al. (1999) Engineering herpes simplex virus vectors for CNS applications. Exp.Neurol. 159, 34–46.

    CAS  Google Scholar 

  27. Dilloo, D., Rill, D., Entwistle, C., Boursnell, M., Zhong, W., Holden, W., et al. (1997) A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood 89, 119–127.

    CAS  Google Scholar 

  28. Tolba, K. A., Bowers, W. J., Hilchey, S. P., Halterman, M. W., Howard, D. F., Giuliano, R. E., et al. (2001) Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood 98, 287–295.

    CAS  Google Scholar 

  29. Jacobs, A., Breakefield, X. O., and Fraefel, C. (1999) HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia 1, 402–416.

    CAS  Google Scholar 

  30. Hill, A., Jugovic, P., York, I., Russ, G., Bennink, J., Yewdell, J., et al. (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375, 411–415.

    CAS  Google Scholar 

  31. Forrester, A., Farrell, H., Wilkinson, G., Kaye, J., Davis-Poynter, N., and Minson, T. (1992) Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. J. Virol. 66, 341–348.

    CAS  Google Scholar 

  32. Krisky, D. M., Wolfe, D., Goins, W. F., Marconi, P. C., Ramakrishnan, R., Mata, M., et al. (1998) Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons.Gene Ther. 5, 1593–1603.

    CAS  Google Scholar 

  33. Spaete, R. R. and Frenkel, N. (1982) The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30, 295–304.

    CAS  Google Scholar 

  34. Saeki, Y., Ichikawa, T., Saeki, A., Chiocca, E. A., Tobler, K., Ackermann, M., et al. (1998) Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. 9, 2787–2794.

    CAS  Google Scholar 

  35. Williams, D. A. and Smith, F. O. (2000) Progress in the use of gene transfer methods to treat genetic blood diseases. Hum. Gene Ther. 11, 2059–2066.

    CAS  Google Scholar 

  36. Cornetta, K., Moore, A., Leemhuis, T., Moen, R. C., Tricot, G., Leibowitz, D., et al. (1994) Retroviral mediated gene transfer in chronic myelogenous leukaemia. Br. J. Haematol. 87, 308–316.

    CAS  Google Scholar 

  37. Roddie, P. H., Paterson, T., and Turner, M. L. (2000) Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines. Cytokines Cell Mol. Ther. 6, 127–134.

    CAS  Google Scholar 

  38. Baum, C., Richters, A., and Ostertag, W. (1999) Retroviral vector-mediated gene expression in hematopoietic cells. Curr. Opin. Mol. Ther. 1, 605–612.

    CAS  Google Scholar 

  39. Miller, A. D. (1992) Retroviral vectors. Curr. Topics Microbiol. Immunol. 158, 1–24.

    CAS  Google Scholar 

  40. Orlic, D., Girard, L. J., Jordan, C. T., Anderson, S. M., Cline, A. P., and Bodine, D. M. (1996) The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc. Natl. Acad. Sci. USA 93, 11,097–11,102.

    CAS  Google Scholar 

  41. Kiem, H. P., Heyward, S., Winkler, A., Potter, J., Allen, J. M., Miller, A. D., et al. (1997) Gene transfer into marrow repopulating cells: comparison between ampho-tropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood 90, 4638–4645.

    CAS  Google Scholar 

  42. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J. K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033–8037.

    CAS  Google Scholar 

  43. Palsson, B. and Andreadis, S. (1997) The physico-chemical factors that govern retrovirus-mediated gene transfer. Exp. Hematol. 25, 94–102.

    CAS  Google Scholar 

  44. Liu, H., Hung, Y., Wissink, S. D., and Verfaillie, C. M. (2000) Improved retroviral transduction of hematopoietic progenitors by combining methods to enhance virus-cell interaction. Leukemia 14, 307–311.

    CAS  Google Scholar 

  45. Hutchings, M., Moriwaki, K., Dilloo, D., Hoffmann, T., Kimbrough, S., Johnsen, H. E., et al. (1998) Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. J. Hematother. 7, 217–224.

    CAS  Google Scholar 

  46. Lee, S. G., Yoon, S. J., Kim, C. D., Kim, K., Lim, D. S., Yeom, Y. I., et al. (2000) Enhancement of adenoviral transduction with polycationic liposomes in vivo.Cancer Gene Ther. 7, 1329–1335.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology and Oncology, University Hospital, Heinrich-Heine-University, Düsseldorf, Germany

    Dagmar Dilloo & Andree Zibert

Authors
  1. Dagmar Dilloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andree Zibert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, University of Leipzig, Leipzig, Germany

    Dieter Körholz  & Wieland Kiess  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Humana Press Inc.

About this protocol

Cite this protocol

Dilloo, D., Zibert, A. (2003). Gene Transfer for Generation of Tumor and Leukemia Vaccines. In: Körholz, D., Kiess, W. (eds) Cytokines and Colony Stimulating Factors. Methods in Molecular Biology, vol 215. Humana, Totowa, NJ. https://doi.org/10.1385/1-59259-345-3:261

Download citation

  • DOI: https://doi.org/10.1385/1-59259-345-3:261

  • Publisher Name: Humana, Totowa, NJ

  • Print ISBN: 978-1-58829-035-9

  • Online ISBN: 978-1-59259-345-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation